- Home
- VIGL vs UMAC Comparison
VIGL vs UMAC Comparison
Compare VIGL & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- UMAC
- Stock Information
- Founded
- VIGL 2020
- UMAC 2019
- Country
- VIGL United States
- UMAC United States
- Employees
- VIGL N/A
- UMAC N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- UMAC
- Sector
- VIGL Health Care
- UMAC
- Exchange
- VIGL Nasdaq
- UMAC Nasdaq
- Market Cap
- VIGL 74.7M
- UMAC N/A
- IPO Year
- VIGL 2022
- UMAC 2024
- Fundamental
- Price
- VIGL $2.41
- UMAC $5.42
- Analyst Decision
- VIGL Strong Buy
- UMAC Strong Buy
- Analyst Count
- VIGL 5
- UMAC 3
- Target Price
- VIGL $16.33
- UMAC $14.00
- AVG Volume (30 Days)
- VIGL 164.4K
- UMAC 1.1M
- Earning Date
- VIGL 05-07-2025
- UMAC 05-08-2025
- Dividend Yield
- VIGL N/A
- UMAC N/A
- EPS Growth
- VIGL N/A
- UMAC N/A
- EPS
- VIGL N/A
- UMAC N/A
- Revenue
- VIGL N/A
- UMAC $5,565,319.00
- Revenue This Year
- VIGL N/A
- UMAC $160.90
- Revenue Next Year
- VIGL N/A
- UMAC $135.75
- P/E Ratio
- VIGL N/A
- UMAC N/A
- Revenue Growth
- VIGL N/A
- UMAC N/A
- 52 Week Low
- VIGL $1.31
- UMAC $1.02
- 52 Week High
- VIGL $6.06
- UMAC $23.62
- Technical
- Relative Strength Index (RSI)
- VIGL 60.07
- UMAC 45.58
- Support Level
- VIGL $1.75
- UMAC $4.91
- Resistance Level
- VIGL $3.00
- UMAC $7.50
- Average True Range (ATR)
- VIGL 0.26
- UMAC 0.52
- MACD
- VIGL 0.08
- UMAC 0.02
- Stochastic Oscillator
- VIGL 55.30
- UMAC 25.71
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.